|
Jul 29
|
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks
|
|
Jul 29
|
FDA places vTv Therapeutics’s cadisegliatin programme on clinical hold
|
|
Jul 26
|
vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink
|
|
Jul 26
|
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
|
|
Jun 24
|
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
|
|
Mar 1
|
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
|
|
Feb 28
|
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
|
|
May 24
|
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
|